BIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the United States and internationally. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems, which are used to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment, including three-dimensional (3D) CAD/CAM intra-oral scanners and digital dentistry software. Its dental imaging products comprise 3Shape Trios intraoral scanners, digital impression systems, and software for taking 3D scans, which are used to design crowns, study models, surgical guides for implant placement, and event orthodontic and athletic appliances. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Phone949-361-1200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$46.93 million
Profitability
Miscellaneous
Employees195
OptionableNot Optionable
BIOLASE (NASDAQ:BIOL) Frequently Asked Questions
What is BIOLASE's stock symbol?
BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."
When did BIOLASE's stock split? How did BIOLASE's stock split work?
Shares of BIOLASE reverse split on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.
How were BIOLASE's earnings last quarter?
BIOLASE Inc (NASDAQ:BIOL) issued its quarterly earnings results on Thursday, August, 9th. The medical technology company reported ($0.20) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.20). The medical technology company had revenue of $12.15 million for the quarter. BIOLASE had a negative net margin of 40.31% and a negative return on equity of 76.74%. View BIOLASE's Earnings History.
When is BIOLASE's next earnings date?
Has BIOLASE been receiving favorable news coverage?
Press coverage about BIOL stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. BIOLASE earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned news coverage about the medical technology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are some of BIOLASE's key competitors?
Who are BIOLASE's key executives?
BIOLASE's management team includes the folowing people:
- Mr. Todd A. Norbe, Pres, CEO & Director (Age 52)
- Mr. John R. Beaver, Exec. VP & CFO (Age 58)
- Mr. Richard R. Whipp, VP of Operations (Age 67)
- Mr. William E. Brown Jr., VP of Bus. Devel. (Age 71)
- Mr. Daniel Merkin, National Sales Director (Age 46)
Who are BIOLASE's major shareholders?
BIOLASE's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Trellus Management Company LLC (0.70%). Company insiders that own BIOLASE stock include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Institutional Ownership Trends for BIOLASE.
Which institutional investors are buying BIOLASE stock?
BIOL stock was acquired by a variety of institutional investors in the last quarter, including Trellus Management Company LLC. Company insiders that have bought BIOLASE stock in the last two years include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Insider Buying and Selling for BIOLASE.
How do I buy shares of BIOLASE?
Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIOLASE's stock price today?
One share of BIOL stock can currently be purchased for approximately $2.09.
How big of a company is BIOLASE?
BIOLASE has a market capitalization of $43.18 million and generates $46.93 million in revenue each year. BIOLASE employs 195 workers across the globe.
What is BIOLASE's official website?
How can I contact BIOLASE?
BIOLASE's mailing address is 4 CROMWELL, IRVINE CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]
MarketBeat Community Rating for BIOLASE (NASDAQ BIOL)
MarketBeat's community ratings are surveys of what our community members think about BIOLASE and other stocks. Vote "Outperform" if you believe BIOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
